Asian Psyllium, commonly known as Plantago ovata or simply psyllium husk, has scientific evidence supporting its use in the management of Inflammatory Bowel Disorders (IBD), particularly ulcerative colitis. Psyllium is a soluble fiber that forms a gel-like substance in the gut, which can help normalize bowel movements and modulate gut microbiota. Several randomized controlled trials and meta-analyses have indicated that psyllium supplementation may be as effective as standard maintenance therapy (such as mesalamine) in keeping patients with ulcerative colitis in remission. For example, a well-known study by Hallert et al. (1991) found that 69% of patients maintained remission with psyllium compared to 70% with mesalamine over a 12-month period, and combining both increased efficacy.

The mechanism is thought to involve psyllium’s ability to increase stool bulk, reduce intestinal transit time, and promote the production of short-chain fatty acids (like butyrate) through fermentation by gut bacteria, which have anti-inflammatory properties and support colonic health. While the evidence is strong for ulcerative colitis, there is less robust data for Crohn's disease, and some patients may experience bloating or discomfort. Overall, psyllium is considered a safe adjunct for many IBD patients, though it should be introduced gradually and with medical supervision.